For many residents in Oshawa and Whitby living on fixed incomes, the high cost of weight-loss and diabetes medication has created a significant barrier to health. However, a “major reset” in pharmaceutical pricing is on the horizon. Healthcare providers across Southern Ontario are reporting that patients without comprehensive drug coverage are closely monitoring Health Canada’s review of generic Ozempic, hoping for a price drop that could make the life-changing medication affordable for the first time.
The Coverage Gap for Durham Seniors
The struggle is exemplified by patients like Anne Welch, a 77-year-old retiree who, despite having a prescription, cannot access the drug through the Ontario Drug Benefit (ODB) program because she does not have a diabetes diagnosis. Under current provincial rules, the ODB only funds the brand-name medication for those with type 2 diabetes.
For seniors in Ajax and Pickering living on Canada Pension Plan (CPP) and Old Age Security (OAS), the out-of-pocket cost of several hundred dollars a month is simply unsustainable. This has led to a growing “hopefulness” around generic Ozempic, as physicians at nearby clinics, including McMaster University’s Hamilton and GTA sites, begin discussing generic alternatives as a near-term solution for obesity treatment.
How Much Will Generic Ozempic Cost?
The potential savings for Durham residents depend on how many manufacturers enter the Canadian market. According to the pricing structure of the pan-Canadian Pharmaceutical Alliance, the cost of semaglutide—the active ingredient in Ozempic—will drop in tiers:
-
First Generic Approved: Price drops to 75–85% of the brand name (approx. $150–$180).
-
Second Generic Approved: Both drop to 50% of the brand name.
-
Three or More Generics: The price could plummet to just 35% of the original cost.
For patients who can “barely squeeze by” on a $150 monthly budget, the arrival of three or more generic options would be the difference between accessing treatment and going without. Currently, nine different generic semaglutide drugs are under review by Health Canada, with some manufactured by international firms like Dr. Reddy’s Laboratories.
Safety and the Complexity of Biologics
While the wait for generic Ozempic is frustrating for those rationing their current supply, Health Canada maintains that the review process is complex. Because the original drug is a biologic—produced using living organisms—the synthetic generic versions must undergo rigorous testing to prove they are pharmaceutically equivalent.
Spokesperson Marie-Pier Burelle noted that the agency is on track with its six-month initial review timelines but must ensure that any differences in the synthetic process do not impact the safety or efficacy for Canadian patients. For the thousands of people in the Durham Region currently caught in the “coverage gap,” the hope is that these more affordable options will hit pharmacy shelves in Oshawa and Whitby by the summer of 2026.
